Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7JFDO)

• Drug Name: Recombinant von Willebrand factor/recombinant Factor VIII complex Drug Info
• Synonyms: Willebrand factor/recombinant Factor VIII complex; Recombinant von Willebrand factor/recombinant Factor VIII complex (von Willebrand disease)

Indication

Disease Entry	ICD 11	Status	REF
Von willebrand disease	3B12	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DM7JFDO

Molecule-Related Drug Atlas

Drug(s) Targeting Coagulation factor VIII (F8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Drotrecogin alfa	DM59JCN	Cerebrovascular ischaemia	8B1Z	Approved	[3]
Factor 8	DMAB6PM	Hemophilia	3B10.0	Approved	[4]
Eloctate	DMRCX8K	Haemophilia A	3B10.0	Approved	[5]
Efanesoctocog alfa	DM2CKIJ	Haemophilia A	3B10.0	Approved	[6]
SK-NBP601	DMUY09W	Hemophilia	3B10.0	Preregistration	[7]
N8-GP	DMY60DT	Factor VIII deficiency	3B10	Phase 3	[8]
OBI-1	DMENDP6	Factor VIII deficiency	3B10	Phase 3	[9]
BAY 94-9027	DM09M3H	Hemophilia	3B10.0	Phase 3	[10]
Plasma derived factor VIII PEGylated liposomal	DM1RWMY	Factor VIII deficiency	3B10	Phase 3	[4]
Turoctocog alfa	DMPBJ8W	Haemophilia A	3B10.0	Phase 3	[11]

Drug(s) Targeting von Willebrand factor (VWF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vonvendi	DMI783H	Von willebrand disease	3B12	Approved	[12]
Caplacizumab	DMPUKA7	Thrombotic thrombocytopenic purpura	3B64.14	Approved	[13]
ALX-0081	DM7EBH9	Thrombotic thrombocytopenic purpura	3B64.14	Phase 3	[14]
ARC1779	DM7PCLY	Intracranial embolism	8B22.1	Phase 2	[15]
BT-200	DM1EYOF	Von willebrand disease	3B12	Phase 2	[16]
DA-697b	DMBRN2G	Thrombosis	DB61-GB90	Phase 1	[17]
DTRI-031	DM0BCT7	Ischemic stroke	8B11.5Z	Phase 1	[18]
Mitoflaxone	DMO06JV	Solid tumour/cancer	2A00-2F9Z	Terminated	[19]
Auryntricarboxylic acid (ATA)	DMOIQ4K	Discovery agent	N.A.	Investigative	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor VIII (F8)	TT1290U	FA8_HUMAN	Modulator	[2]
von Willebrand factor (VWF)	TT3SZBT	VWF_HUMAN	Modulator	[2]

References

• [1] FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes. PLoS One. 2015 Apr 23;10(4):e0124930.
• [2] 6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418.
• [3] Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
• [5] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [6] Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022 Feb 22;6(4):1089-1094.
• [7] Clinical pipeline report, company report or official report of SK Chemicals.
• [8] Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013 Apr;11(4):670-8.
• [9] Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015 Mar;21(2):162-70.
• [10] Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014 Apr;12(4):488-96.
• [11] The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight ), in patients with hemophilia A. J Thromb Haemost. 2015 Mar;13(3):370-9.
• [12] Clinical pipeline report, company report or official report of Vonvendi.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [14] Clinical pipeline report, company report or official report of Ablynx
• [15] Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2028-2037.
• [16] Clinical pipeline report, company report or official report of Guardian Theapeutics
• [17] A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010 Jan;103(1):205-12.
• [18] Clinical pipeline report, company report or official report of Basking Biosciences
• [19] Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.